Website
News25/Ratings12
News · 26 weeks43+150%
2025-10-262026-04-19
Mix2290d
- Insider12(55%)
- SEC Filings4(18%)
- Other3(14%)
- Earnings2(9%)
- Analyst1(5%)
Latest news
25 items- PROmnicell to Release First Quarter 2026 Financial Results on April 28, 2026Omnicell, Inc. (NASDAQ:OMCL), a leading healthcare technology provider focused on empowering autonomous medication management, will release its financial results for the first quarter 2026, before market open on Tuesday, April 28, 2026. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day. All interested parties are invited to listen to the live call and presentation by dialing (800) 715-9871 in the U.S. or (646) 307-1963 in international locations. The Conference ID is 9381205. A link to the live and archived webcast will also be available on the Investor Relations section of Omnicell's website at https://ir.omnicell.com/event
- SECSEC Form DEF 14A filed by Omnicell Inc.DEF 14A - OMNICELL, INC. (0000926326) (Filer)
- PRAI-Driven Compliance Gamechanger in Pharma Manufacturing and Regulatory StandardsAUSTIN, Texas, April 07, 2026 (GLOBE NEWSWIRE) -- AINewsWire Editorial Coverage: As regulatory expectations intensify and manufacturing complexity grows, pharmaceutical companies are moving beyond traditional quality systems toward a new paradigm: embedding artificial intelligence (AI) directly into operations as a real-time compliance layer. Rather than relying on retrospective audits and manual oversight, AI-driven systems now continuously monitor, validate and optimize production processes to align with evolving Good Manufacturing Practice (GMP) standards. This structural shift is increasingly visible across the industry and aligns with companies such as Oncotelic Therapeutics Inc. (OTC
- INSIDERSEC Form 4 filed by Njoku Nnamdi4 - OMNICELL, INC. (0000926326) (Issuer)
- INSIDERSEC Form 4 filed by Manley Corey J4 - OMNICELL, INC. (0000926326) (Issuer)
- INSIDERSEC Form 4 filed by Nutt Brian H.4 - OMNICELL, INC. (0000926326) (Issuer)
- INSIDERSEC Form 4 filed by Radford Harlan Baird4 - OMNICELL, INC. (0000926326) (Issuer)
- INSIDERSEC Form 4 filed by Lipps Randall A4 - OMNICELL, INC. (0000926326) (Issuer)
- SECSEC Form PRE 14A filed by Omnicell Inc.PRE 14A - OMNICELL, INC. (0000926326) (Filer)
- SECSEC Form SCHEDULE 13G filed by Omnicell Inc.SCHEDULE 13G - OMNICELL, INC. (0000926326) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Omnicell Inc.SCHEDULE 13G/A - OMNICELL, INC. (0000926326) (Subject)
- INSIDERCHAIRMAN, PRESIDENT AND CEO Lipps Randall A was granted 79,494 shares and covered exercise/tax liability with 15,642 shares, increasing direct ownership by 17% to 444,592 units (SEC Form 4)4 - OMNICELL, INC. (0000926326) (Issuer)
- INSIDEREVP, Chief Operating Officer Njoku Nnamdi was granted 37,409 shares and covered exercise/tax liability with 8,456 shares, increasing direct ownership by 34% to 115,239 units (SEC Form 4)4 - OMNICELL, INC. (0000926326) (Issuer)
- INSIDEREVP&CHIEF LEGAL/ADMIN OFFICER Manley Corey J was granted 22,445 shares, covered exercise/tax liability with 3,819 shares and sold $256,879 worth of shares (7,405 units at $34.69), increasing direct ownership by 13% to 96,717 units (SEC Form 4)4 - OMNICELL, INC. (0000926326) (Issuer)
- SECSEC Form 10-K filed by Omnicell Inc.10-K - OMNICELL, INC. (0000926326) (Filer)
- INSIDERVP, Chief Accounting Officer Nutt Brian H. covered exercise/tax liability with 258 shares, decreasing direct ownership by 1% to 17,530 units (SEC Form 4)4 - OMNICELL, INC. (0000926326) (Issuer)
- INSIDEREVP, Chief Operating Officer Njoku Nnamdi covered exercise/tax liability with 1,146 shares, decreasing direct ownership by 1% to 86,286 units (SEC Form 4)4 - OMNICELL, INC. (0000926326) (Issuer)
- INSIDEREVP&CHIEF LEGAL/ADMIN OFFICER Manley Corey J covered exercise/tax liability with 2,022 shares and sold $155,251 worth of shares (4,243 units at $36.59), decreasing direct ownership by 7% to 85,496 units (SEC Form 4)4 - OMNICELL, INC. (0000926326) (Issuer)
- INSIDERCHAIRMAN, PRESIDENT AND CEO Lipps Randall A covered exercise/tax liability with 5,294 shares, decreasing direct ownership by 1% to 380,740 units (SEC Form 4)4 - OMNICELL, INC. (0000926326) (Issuer)
- SECOmnicell Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - OMNICELL, INC. (0000926326) (Filer)
- PROmnicell Announces Fiscal Year and Fourth Quarter 2025 Financial ResultsOmnicell delivers solid fourth quarter 2025 financial results Announces major step toward autonomous medication management with the launch of its next generation dispensing system, Titan XT, at the American Society of Health-System Pharmacists (ASHP) 2025 Midyear Clinical Meeting & Exhibition Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leading healthcare technology provider focused on empowering autonomous medication management, today announced results for its fiscal year and fourth quarter ended December 31, 2025. "We finished 2025 with solid fourth quarter financial results, delivering full year 2025 total revenues, product booking
- ANALYSTOmnicell upgraded by BofA Securities with a new price targetBofA Securities upgraded Omnicell from Neutral to Buy and set a new price target of $70.00
- PROmnicell to Release Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026Omnicell, Inc. (NASDAQ:OMCL), a leading healthcare technology provider focused on empowering autonomous medication management, will release its financial results for the fourth quarter and full year 2025, before market open on Thursday, February 5, 2026. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day. All interested parties are invited to listen to the live call and presentation by dialing (800) 715-9871 in the U.S. or (646) 307-1963 in international locations. The Conference ID is 4203777. A link to the live and archived webcast will also be available on the Investor Relations section of Omnicell's website at https://ir.
- INSIDEREVP&CHIEF LEGAL/ADMIN OFFICER Manley Corey J sold $304,689 worth of shares (6,106 units at $49.90), decreasing direct ownership by 6% to 91,674 units (SEC Form 4)4 - OMNICELL, INC. (0000926326) (Issuer)
- ANALYSTOmnicell upgraded by KeyBanc Capital Markets with a new price targetKeyBanc Capital Markets upgraded Omnicell from Sector Weight to Overweight and set a new price target of $60.00